Stay updated on Dupilumab in ABPA Treatment Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in ABPA Treatment Clinical Trial page.

Latest updates to the Dupilumab in ABPA Treatment Clinical Trial page
- Check3 days agoChange DetectedMinor revision label updated from v3.3.3 to v3.3.4 on the page, with no changes to study content, enrollment, outcomes, or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedLocations section expanded to include Alabama, Arizona, California, Idaho, Iowa, New York, Ohio, Pennsylvania, Saxony, North Holland, Bihor County, England, and West Yorkshire; the HHS Vulnerability Disclosure footer link was removed and the revision updated to v3.3.3.SummaryDifference1%

- Check53 days agoChange DetectedPublications section updated to say publications are automatically filled from PubMed and may not be about the study, with the revision labeled v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedDeletion of the government funding notice from the study page. The notice previously warned that information may not be up to date and directed users to NIH and OPM status pages.SummaryDifference0.3%

- Check74 days agoChange DetectedNo significant additions or deletions were observed on the Study Details page (NCT04442269); the content and layout appear the same.SummaryDifference0.3%

- Check103 days agoChange DetectedAdded a government-operating-status notice and a version bump to v3.2.0; removed the previous version tag v3.1.0.SummaryDifference3%

Stay in the know with updates to Dupilumab in ABPA Treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in ABPA Treatment Clinical Trial page.